TRVN (Trevena) Short-Term Debt : $0.90 Mil (As of Sep. 2024)

View and export this data going back to 2014. Start your Free Trial

What is Trevena Short-Term Debt?

Trevena's Short-Term Debt for the quarter that ended in Sep. 2024 was $0.90 Mil.

Trevena's quarterly Short-Term Debt stayed the same from Mar. 2024 ($0.00 Mil) to Jun. 2024 ($0.00 Mil) but then increased from Jun. 2024 ($0.00 Mil) to Sep. 2024 ($0.90 Mil).

Trevena Short-Term Debt Historical Data

The historical data trend for Trevena's Short-Term Debt can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Trevena Short-Term Debt Chart

Trevena Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Short-Term Debt

Get a 7-Day Free Trial

5.04

Trevena Quarterly Data
	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24
Short-Term Debt	Get a 7-Day Free Trial															-	-	-	-	0.90

Trevena Short-Term Debt Explanation

Short-Term Debt represents the total amount of Long-Term Debt such as bank loans and commercial paper, which is due within one year.

Trevena Short-Term Debt Related Terms

Thank you for viewing the detailed overview of Trevena's Short-Term Debt provided by GuruFocus.com. Please click on the following links to see related term pages.

Trevena Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Trevena Inc (OTCPK:TRVN) » Definitions » Short-Term Debt

Comparable Companies

Traded in Other Exchanges

N/A

Address

955 Chesterbrook Boulevard, Suite 110, Chesterbrook, PA, USA, 19087

Website

https://www.trevena.com

Trevena Inc is an American biopharmaceutical company focused on developing and commercializing novel medicines for patients affected by central nervous system, or CNS, disorders.

Executives

Mark Corrigan	director
Mark Demitrack	officer: SVP, Chief Medical Officer	955 CHESTERBROOK BOULEVARD, SUITE 200, CHESTERBROOK PA 19087
Robert T Yoder	officer: SVP, Chief Business Officer	955 CHESTERBROOK BOULEVARD, SUITE 110, SUITE 200, CHESTERBROOK PA 19087
Carrie L. Bourdow	director, officer: President & CEO	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Patricia M. Drake	officer: SVP, Chief Commercial Officer	245 FIRST STREET, SUITE 1800, CAMBRIDGE MA 02142
Barry Shin	officer: SVP, CFO	C/O TREVENA, INC., 955 CHESTERBROOK BLVD, SUITE 110, CHESTERBROOK PA 19087
Marvin Johnson	director	C/O TREVENA, INC., 955 CHESTERBROOK BOULEVARD, STE. 110, CHESTERBROOK PA 19087
Barbara Yanni	director	1018 W. 8TH AVENUE, SUITE A, KING OF PRUSSIA PA 19406
Moulder Leon O Jr	director	C/O TESARO, INC., 1000 WINTER STREET, SUITE 3300, WALTHAM MA 02451
Jason Raleigh Nunn	director	1119 ST. PAUL STREET, BALTIMORE MD 21202
Scott Braunstein	director	C/O ESPERION THERAPEUTICS, INC., 3891 RANCHERO DRIVE, SUITE 150, ANN ARBOR MI 48108
Michael R Dougherty	director	C/O ADOLOR CORP, 700 PENNSYLVANIA DR, EXTON PA 19341
Anne M. Phillips	director	C/O TREVENA, INC., 1018 WEST 8TH AVENUE, KING OF PRUSSIA PA 19406
Scott Applebaum	officer: CLCO; SVP, Regulatory Affairs	C/O TREVENA INC., 955 CHESTERBROOK BOULEVARD, SUITE 110, CHESTERBROOK PA 19087
John P. Hamill	officer: Int. Prin. Fin. Off. and PAO	4092 NEW HOPE ROAD, FURLONG PA 18925